샘플 요청 목록

 카트 문의
시장보고서
상품코드
1944437

RWE(Real World Evidence) 솔루션 시장 : 치료 분야별, 구성요소별, 용도별, 최종 용도별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율, 예측(2025-2032년)

Real World Evidence Solutions Market, By Therapeutic Area, By Component, By Application, By End Use, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 301 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

RWE(Real World Evidence) 솔루션 시장 규모는 2024년에 27억 9,509만 달러로 평가되었으며, 2025년부터 2032년까지 CAGR 8.90%로 확대될 전망입니다.

RWE(Real World Evidence) 솔루션은 전자건강기록, 청구 데이터베이스, 레지스트리, 환자 생성 데이터 등 실제 데이터 소스로부터 임상적 인사이트를 창출하여 의료기관, 생명과학 기업, 규제 당국을 지원하기 위해 설계된 데이터 기반 분석 플랫폼입니다. 데이터 기반 플랫폼 및 분석 툴을 말합니다. 이들은 고도의 분석, 인공지능, 머신러닝을 활용하여 실제 임상 현장에서의 치료 효과, 안전성, 결과를 평가합니다. 이러한 솔루션은 의약품 개발, 규제 당국 신청, 시판 후 조사에서 의사결정을 개선하는 데 기여합니다. 기존 임상시험에 대한 의존도를 낮춰 근거창출을 강화하고, 가치 기반 의료를 지원합니다. RWE(Real World Evidence) 솔루션은 데이터 기반 의료 혁신과 맞춤형 치료 전략을 실현하는 데에도 중요한 역할을 합니다.

RWE(Real World Evidence) 솔루션의 시장 역학

데이터 기반 의료 의사결정에 대한 수요 증가

데이터 기반 의료 의사결정에 대한 수요 증가는 의료 생태계 전반에서 임상, 규제, 정책적 의사결정을 이끌어내기 위해 실제 데이터와 고급 분석에 대한 의존도가 높아지고 있다는 것을 의미합니다. RWE(Real World Evidence) 솔루션 시장에서는 이러한 수요가 전자건강기록, 청구 데이터, 환자 등록 정보 등 대규모 데이터 소스의 통합을 촉진하여 실용적인 인사이트를 창출하는 데 기여하고 있습니다. RWE 솔루션을 통해 이해관계자들은 통제된 시험 환경을 넘어 실제 임상 현장에서 치료 효과, 안전성, 결과를 평가할 수 있습니다. 그 결과, 의료 제공자, 제약사, 규제 당국은 환자 결과를 개선하고 의료 비용을 최적화할 수 있는 근거에 기반한 의사결정을 더 잘 내릴 수 있게 됩니다. 또한, 데이터 기반 인사이트의 활용은 가치 기반 의료, 맞춤형 치료 전략, 시판 후 조사 등을 지원합니다. 전반적으로 실제 데이터에 대한 관심이 높아지면서 의료 및 생명과학 산업 전반에 걸쳐 RWE 솔루션의 도입과 확장성이 강화되고 있습니다. 예를 들어, 영국 정부의 분석에 따르면, 2023년 기준 영국에는 약 9,600개의 데이터 기반 기업이 존재하며, 연간 총 매출은 약 3,430억 파운드(국내 총 사업 매출의 약 6%)에 달하고, 약 150만 명의 고용을 창출하고 있습니다. 이들 조직은 고용을 통해 약 849억 파운드의 총 부가가치(GVA)를 창출한 것으로 추정되며, 이는 영국 경제 전반에 걸쳐 데이터 기반 디지털 기업의 경제적 영향력이 확대되고 있음을 보여줍니다. 이는 의료 의사결정에 있어 실제 데이터 활용에 대한 강력한 제도적, 규제적 지원을 보여주며, 임상적 성과와 업무 효율성을 향상시키기 위한 데이터 기반 솔루션 도입의 광범위한 추세를 강조합니다. RWE()에 대한 의존도가 높아짐에 따라 의료 이해관계자들은 실제 환자 데이터와 임상 데이터에서 얻은 실용적인 인사이트를 활용하여 치료 정책, 상환 및 정책 결정을 보다 현명하게 내릴 수 있게 되었습니다.

RWE(Real World Evidence) 솔루션 시장 : 세분화 분석

세계 RWE(Real World Evidence) 솔루션 시장은 치료 영역, 구성요소, 용도, 최종 용도, 지역을 기준으로 세분화되어 있습니다.

구성요소를 기반으로 한 시장 세분화는 솔루션, 서비스, 플랫폼/기술의 세 가지 범주로 나뉩니다. 솔루션 분야는 실용적인 현실세계의 지식을 생성하는 능력으로 인해 시장에서 큰 비중을 차지하고 있습니다. 실용적 지식 생성은 임상적 판단, 규제 당국 신청, 시장 접근 전략을 지원하기 위해 실제 데이터에서 의미 있는 정보를 추출하는 전략과 프로세스를 의미합니다. 여기에는 다양한 의료 데이터 소스의 통합, 첨단 분석 기술의 적용, 치료, 안전성 및 유효성 평가에 기여하는 근거 기반의 결과물 제공 등이 포함됩니다. 이러한 지식의 제공은 의사결정을 강화하고, 업무 효율성을 향상시키며, 의료 이해관계자들이 환자의 치료 결과를 효과적으로 최적화할 수 있도록 돕습니다. RWE 솔루션은 소프트웨어 플랫폼, 분석 도구, 데이터 시각화 솔루션을 통해 실용적인 인사이트를 실현하여 조직이 실제 데이터를 신속하게 분석하고, 데이터의 정확성을 보장하며, 임상적 및 경영적 판단을 위한 신뢰할 수 있는 증거를 제공할 수 있도록 지원합니다. 예를 들어, 영국 의약품의료제품규제청(MHRA)이 발표한 'MHRA 데이터 전략 2024-2027'은 탄탄한 데이터 인프라, 도구, 전문 지식을 구축하고, 실제 데이터(RWD)에 대한 접근성을 강화하며, 의료제품의 라이프사이클 전반에 걸쳐 엄격한 규제 판단을 지원하기 위해 실용적인 RWE(Real World Evidence)를 생성하기 위한 계획을 제시합니다. 이번 전략은 데이터 통합 개선, 첨단 분석 기술 활용, 규제 과학을 위한 역량 강화, 혁신적인 제품에 대한 조기 접근 및 업무 효율성 향상, 기술 개발, 파트너십 촉진, 인공지능을 활용한 공중보건 성과 향상을 위한 지식 창출에 초점을 맞추고 있습니다.

시장은 용도에 따라 의약품 개발 및 신약개발과 시장 접근 및 상업화의 두 가지 범주로 나뉩니다. 시장 접근 및 상업화 부문은 상환, 가격 책정, 의료 경제성 의사결정을 지원하는 데 필수적인 역할을 수행하기 때문에 RWE(Real World Evidence) 솔루션 시장을 주도하고 있습니다. RWE에 대한 의존도가 높아지는 것은 제약 및 생명공학 기업들이 제품의 가치를 입증하고 시장 접근을 최적화해야 할 필요성이 증가하고 있음을 반영합니다. 상환 및 상업화 의사결정을 지원한다는 것은 RWE를 활용하여 가격 책정, 보험 적용 및 시장 진입 전략을 안내하는 강력하고 실용적인 인사이트를 창출하는 것을 의미합니다. 이를 통해 조직은 정보에 입각한 증거 기반 의사결정을 내리고, 업무 효율성을 개선하며, 경쟁 우위를 강화할 수 있습니다. 이 부문의 RWE 솔루션은 기업이 다양한 인구집단의 실제 데이터를 분석하고, 치료 결과를 평가하며, 시장 접근 및 상업화 전략을 강화할 수 있는 인사이트를 제공할 수 있도록 지원합니다. 예를 들어, 2025년 9월 미국 국립보건원(NIH)에 따르면, 스코프 리뷰 '의료 보험자의 RWE 활용'에서 2014년부터 2025년 3월까지 발표된 1만 3,655편의 논문을 조사했으며, 그 중 19편의 연구가 전체 리뷰 대상으로 선정되었습니다. 이는 표준화 및 근거의 질에 대한 지속적인 과제에도 불구하고, 보험사가 자금 조달 및 상환 결정에 있어 RWE(Real World Evidence)를 활용하는 것에 대한 관심이 증가하고 있음을 보여줍니다. 이러한 광범위한 채택은 RWE 인프라가 점점 더 성숙해지고 있으며, AI 기반 및 고급 분석 솔루션이 실제 데이터에 대한 확장 가능한 액세스를 제공하고, 의료 및 연구 시스템 간의 상호 운용성을 강화하며, 시장 접근, 상환, 가격 책정 및 상업화 의사결정을 지원하기 위해 RWE를 점점 더 많이 활용하고 있음을 보여줍니다. 위한 RWE의 활용을 증가시키고 있다는 보다 광범위한 추세를 반영하고 있습니다.

RWE(Real World Evidence) 솔루션 시장 - 지역별 분석

RWE(Real World Evidence) 솔루션 시장은 의료 데이터 인프라, 규제 프레임워크, 디지털 헬스 기술 도입 현황의 영향을 받아 지역별로 뚜렷한 차이를 보이고 있습니다. 북미에서는 기존 의료 시스템, 제약 및 생명공학 기업, 지불 기관이 RWE를 광범위하게 활용하고 있으며, 특히 미국과 캐나다에서 시장 접근, 상환 및 규제 결정에 대한 실제 데이터에 대한 의존도가 높은 것이 도입을 주도하고 있습니다. 유럽에서는 실세계 데이터 이니셔티브에 대한 투자 증가, RWE에 대한 조화로운 규제 지침, 의료 기술 평가 및 보험사의 보험 적용 평가에 대한 RWE 활용 확대로 인해 RWE가 꾸준히 확대되고 있습니다. 아시아태평양에서는 의료의 디지털화 진전, 전자건강기록(EHR) 보급 확대, 대규모 환자 인구, 중국, 인도, 일본, 한국 등의 정부 지원이 RWE 솔루션의 도입을 가속화하고 있습니다. 한편, 라틴아메리카, 중동 및 아프리카에서는 의료 인프라 개선, RWE 적용에 대한 인식 개선, 임상 및 상환 관련 지식을 얻기 위한 실제 데이터 활용에 대한 지불자 및 제공자의 관심 증가를 배경으로 점차 존재감을 강화하고 있습니다.

미국 RWE(Real World Evidence) 솔루션 시장 - 국가별 분석

미국 내 RWE(Real World Evidence) 솔루션 시장은 기존 의료 시스템과 디지털 헬스 기술의 통합 발전에 힘입어 꾸준히 성장하고 있습니다. 제약사, 생명공학 기업, 지불 기관은 시장 진입, 상환, 규제 판단, 가치 기반 의료 전략 수립을 위해 RWE 솔루션을 활용하고 있습니다. 주요 솔루션 제공업체들의 적극적인 참여와 더불어, 실제 데이터 활용을 촉진하는 규제 프레임워크의 발전이 시장 확대를 견인하고 있습니다. 또한, 근거에 기반한 의사결정, 업무 효율성, 지불자와 이해관계자에 대한 제품 가치 증명에 대한 관심이 높아지면서 의료 및 연구 현장 전반에 걸쳐 RWE 솔루션 도입이 가속화되고 있습니다.

JMIR Formative Research에 게재된 연구에 따르면, 영국의 106개 국민보건서비스 임상위탁그룹(CCG)의 135개 연례보고서(2020-2021년 18,667페이지 분량의 데이터)를 분석한 결과, 9개의 디지털 테마로 분류되는 31개의 디지털 기술이 확인되었습니다. 9개의 디지털 테마로 분류되는 31개의 디지털 기술이 확인되었습니다. 이 중 98.1%의 CCG가 온라인 선별진료소를, 82%가 원격의료를 도입한 것으로 보고되어, COVID-19 팬데믹 기간과 그 이후에도 서비스 제공과 환자 접근성을 개선하기 위한 디지털 도구의 광범위한 도입이 이루어지고 있음을 알 수 있습니다. 이러한 결과는 환자 참여 강화, 원격 모니터링 지원, 의료 서비스 확대를 위한 디지털 기술의 NHS 조직 내 통합을 뒷받침하는 동시에 CCG 간 디지털 도입의 지역적 차이를 반영하고 있습니다.

목차

제1장 RWE(Real World Evidence) 솔루션 시장 개요

제2장 주요 요약

제3장 RWE(Real World Evidence) 솔루션의 주요 시장 동향

제4장 RWE(Real World Evidence) 솔루션 시장 : 산업 분석

제5장 RWE(Real World Evidence) 솔루션 시장 : 높아지는 지정학적 긴장의 영향

제6장 RWE(Real World Evidence) 솔루션 시장 구도

제7장 RWE(Real World Evidence) 솔루션 시장 : 치료 분야별

제8장 RWE(Real World Evidence) 솔루션 시장 : 구성요소별

제9장 RWE(Real World Evidence) 솔루션 시장 : 용도별

제10장 실세계 데이터 솔루션 시장 : 최종 용도별

제11장 RWE(Real World Evidence) 솔루션 시장 : 지역별

제12장 주요 벤더 분석 : RWE(Real World Evidence) 솔루션 산업

제13장 AnalystView의 전방위적 분석

KSM

Real World Evidence Solutions Market size was valued at US$ 2,795.09 Million in 2024, expanding at a CAGR of 8.90% from 2025 to 2032.

Real World Evidence (RWE) Solutions refer to data-driven platforms and analytical tools designed to support healthcare organizations, life science companies, and regulators by generating clinical insights from real-world data sources such as electronic health records, claims databases, registries, and patient-generated data. They leverage advanced analytics, artificial intelligence, and machine learning to evaluate treatment effectiveness, safety, and outcomes in real-life clinical settings. These solutions help improve decision-making across drug development, regulatory submissions, and post-market surveillance. By reducing reliance on traditional clinical trials alone, they enhance evidence generation and support value-based healthcare. Real World Evidence solutions also play a key role in enabling data-driven healthcare innovation and personalized treatment strategies.

Real World Evidence Solutions Market- Market Dynamics

Rising demand for data-driven healthcare decisions

Rising demand for data-driven healthcare decisions refers to the increasing reliance on real-world data and advanced analytics to guide clinical, regulatory, and policy decision-making across the healthcare ecosystem. In the Real World Evidence (RWE) Solutions market, this demand drives the integration of large-scale data sources such as electronic health records, claims data, and patient registries to generate actionable insights. RWE solutions enable stakeholders to evaluate treatment effectiveness, safety, and outcomes in real-world clinical settings beyond controlled trials. Consequently, healthcare providers, pharmaceutical companies, and regulators are better equipped to make evidence-based decisions that improve patient outcomes and optimize healthcare spending. Moreover, the use of data-driven insights supports value-based care, personalized treatment strategies, and post-market surveillance. Overall, the growing emphasis on real-world data strengthens the adoption and scalability of RWE solutions across the healthcare and life sciences industries. For instance, according to UK government analysis, in 2023 the UK hosted approximately 9,600 data-driven businesses that together generated about £343 billion in annual revenue, accounting for nearly 6% of total business turnover nationwide, while employing around 1.5 million people. These organizations also delivered an estimated £84.9 billion in Gross Value Added (GVA) through employment, highlighting the expanding economic impact of data-driven and digital enterprises across the UK economy. This highlights strong institutional and regulatory backing for leveraging real-world data in healthcare decision-making and emphasizes the broader trend of adopting data-driven solutions to enhance clinical outcomes and operational efficiency. Increasing reliance on real-world evidence allows healthcare stakeholders to make more informed treatment, reimbursement, and policy decisions by utilizing actionable insights derived from real-world patient and clinical data.

Real World Evidence Solutions Market- Segmentation Analysis:

The Global Real World Evidence Solutions Market is segmented on the basis of Therapeutic Area, Component, Application, End Use, and Region.

The market is divided into three categories based on Component: Solution, Services, and Platform/Technology. The Solution segment accounts for a significant portion of the market due to its ability to generate actionable real-world insights. Generating actionable insights refers to strategies and processes aimed at extracting meaningful information from real-world data to support clinical decisions, regulatory submissions, and market access strategies. This involves integrating diverse healthcare data sources, applying advanced analytics, and providing evidence-based outputs to inform treatment, safety, and effectiveness evaluations. Delivering these insights enhances decision-making, improves operational efficiency, and enables healthcare stakeholders to optimize patient outcomes effectively. In RWE solutions, actionable insights are achieved through software platforms, analytics tools, and data visualization solutions that help organizations analyze real-world data quickly, ensure data accuracy, and provide reliable evidence for clinical and business decisions. For instance, the MHRA Data Strategy 2024-2027, published by the UK Medicines and Healthcare products Regulatory Agency, sets out a plan to build a strong data infrastructure, tools, and expertise to enhance access to real-world data (RWD) and produce actionable real-world evidence (RWE) that supports rigorous regulatory decisions throughout the medical product lifecycle. The strategy emphasizes improving data integration, leveraging advanced analytics, and strengthening capabilities to guide regulatory science, enable earlier access to innovative products, and boost operational efficiency, while also focusing on skill development, fostering partnerships, and utilizing artificial intelligence to generate insights that advance public health outcomes.

The market is divided into two categories based on Application: Drug Development & Discovery and Market Access & Commercialization. The Market Access & Commercialization segment dominates the Real World Evidence (RWE) Solutions market due to its essential role in supporting reimbursement, pricing, and health economics decisions. The rising reliance on RWE reflects the growing need among pharmaceutical and biotechnology companies to demonstrate product value and optimize market access. Supporting reimbursement and commercialization decisions means leveraging RWE to generate robust, actionable insights that guide pricing, coverage, and market entry strategies. This enables organizations to make informed, evidence-based decisions, improve operational efficiency, and strengthen competitive positioning. RWE solutions in this segment help companies analyze real-world data across diverse populations, evaluate treatment outcomes, and deliver insights that enhance market access and commercialization strategies. For instance, in September 2025, according to the National Institutes of Health, the scoping review "The Use of Real-World Evidence Among Healthcare Payers" examined 13,655 articles published between 2014 and March 2025, of which 19 studies were selected for full-text review, highlighting the growing interest of payers in leveraging real-world evidence (RWE) to inform funding and reimbursement decisions, despite ongoing challenges related to standardization and evidence quality. This broad adoption highlights the growing maturity of RWE infrastructure and reflects wider trends where AI-driven and advanced analytics solutions are providing scalable access to real-world data, enhancing interoperability across healthcare and research systems, and increasing the use of RWE to support market access, reimbursement, pricing, and commercialization decisions.

Real World Evidence Solutions Market- Geographical Insights

The Real World Evidence (RWE) Solutions market exhibits notable regional variations influenced by healthcare data infrastructure, regulatory frameworks, and adoption of digital health technologies. In North America, adoption is driven by well-established healthcare systems, extensive use of RWE by pharmaceutical, biotechnology, and payer organizations, and reliance on real-world data for market access, reimbursement, and regulatory decisions, particularly in the U.S. and Canada. Europe is seeing steady expansion due to increased investments in real-world data initiatives, harmonized regulatory guidance on RWE, and growing use of RWE in health technology assessments and payer coverage evaluations. In Asia Pacific region, rising healthcare digitization, greater adoption of electronic health records, large patient populations, and government support in countries such as China, India, Japan, and South Korea are accelerating the uptake of RWE solutions. At the same time, Latin America, the Middle East, and Africa are gradually strengthening their presence, supported by improvements in healthcare infrastructure, increased awareness of RWE applications, and growing interest among payers and providers in leveraging real-world data for clinical and reimbursement insights.

United States Healthcare Virtual Assistant Market - Country Insights

The U.S. Real World Evidence (RWE) Solutions market is experiencing consistent growth, supported by a well-established healthcare system and the increasing integration of digital health technologies. Pharmaceutical, biotechnology, and payer organizations are leveraging RWE solutions to inform market access, reimbursement, regulatory decisions, and value-based care strategies. Active participation from leading solution providers, along with evolving regulatory frameworks that promote the use of real-world data, is driving further market expansion. In addition, the growing focus on evidence-based decision-making, operational efficiency, and demonstrating product value to payers and stakeholders is accelerating the adoption of RWE solutions across healthcare and research settings.

According to research published in JMIR Formative Research, an analysis of 135 annual reports from 106 National Health Service clinical commissioning groups (CCGs) in England, covering 18,667 pages of data from 2020 to 2021, identified 31 types of digital technologies across nine digital themes. Among these, online triage was reported by 98.1 % of CCGs and telehealth by 82 %, highlighting the widespread adoption of digital tools to improve service delivery and patient access during and after the COVID-19 pandemic. These results underscore the integration of digital technologies within NHS organizations to enhance patient engagement, support remote monitoring, and expand healthcare delivery, while also reflecting regional differences in digital adoption across CCGs.

Real World Evidence Solutions Market- Competitive Landscape:

The Real World Evidence (RWE) Solutions market is moderately concentrated, with several leading technology and analytics providers driving competition. Key players include IQVIA, Oracle Health Sciences, IBM Watson Health, Medidata Solutions, Parexel, PAREXEL Informatics, ICON plc, Syneos Health, Veeva Systems, Evidera, Optum, and Covance (Labcorp Drug Development). These companies compete by offering comprehensive RWE solutions, including real-world data integration, advanced analytics, regulatory and payer reporting, market access support, and value-based care insights, enabling pharmaceutical, biotechnology, and payer organizations to make evidence-based clinical, commercial, and reimbursement decisions. For instance, between 2023 and 2025, IQVIA enhanced its real-world evidence capabilities by further developing its Connected Intelligence platform, incorporating advanced analytics, artificial intelligence, and extensive real-world data assets to support regulatory, reimbursement, and market access decision-making. These advancements enabled life sciences companies and payers to generate more reliable and actionable insights across the product lifecycle, from clinical development through commercialization. The market is being driven by increasing demand for robust real-world evidence to inform reimbursement, pricing, and value-based care strategies. In response, IQVIA and similar providers are expanding their portfolios to include longitudinal data integration, AI-enabled analytics, regulatory-grade evidence generation, and cloud-based RWE solutions, aligning with the growing need for scalable, high-quality, and decision-ready real-world insights.

Recent Developments:

In March 2025, ICON plc (Ireland) launched its PatientSourceDuo data asset, a real-world data solution that links healthcare claims and patient journey data to support comprehensive analysis across the product lifecycle. This initiative enhances ICON's ability to generate actionable evidence for post-marketing safety and efficacy insights, strengthening its offerings in RWE-driven research and commercial evidence strategies. The development reflects ICON's commitment to expanding its real-world data ecosystem and analytics capabilities to better support pharmaceutical and biotechnology clients in evidence generation and decision-making.

In July 2025, Syneos Health (US) announced a strategic partnership with KX to advance data-driven transformation in biopharmaceutical asset development, leveraging predictive analytics and AI-enabled solutions to improve clinical trial efficiency and reduce time to market for new therapies. This initiative highlights Syneos Health's commitment to enhancing real-world evidence and advanced analytics capabilities, enabling clients to tackle complex clinical and commercial decisions more effectively. The collaboration is designed to accelerate real-world data insights, support faster trial site selection, and unlock deeper analytical insights across clinical and commercial functions, positioning Syneos Health as a competitive provider of integrated RWE and biopharmaceutical solutions.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL REAL WORLD EVIDENCE SOLUTIONS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Optum Inc.
  • SAS Institute Inc.
  • Parexel International Corporation
  • Aetion, Inc.
  • Oracle
  • Trinity
  • Icon Plc
  • Merative
  • IQVIA
  • Cegedim Health Data
  • Syneos Health
  • Flatiron Health
  • Cytel Inc.
  • NTT DATA, Inc.
  • Cognizant
  • Medpace
  • Others

GLOBAL REAL WORLD EVIDENCE SOLUTIONS MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

  • Respiratory
  • Neurology
  • Psychiatry
  • Oncology
  • Cardiology
  • Diabetes
  • Others

GLOBAL REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT - MARKET ANALYSIS, 2019 - 2032

  • Data sets
  • Services

GLOBAL REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION - MARKET ANALYSIS, 2019 - 2032

  • Post Market Safety & Adverse Events Monitoring
  • Reimbursement/Coverage and Regulatory Decision Making
  • Drug Development & Approvals
  • Medical Device Development & Approvals
  • Clinical and regulatory decision-making

GLOBAL REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USE- MARKET ANALYSIS, 2019 - 2032

  • Healthcare Payers
  • Healthcare Providers
  • Healthcare Companies (Pharmaceutical, Biopharmaceutical, Medical Device)
  • Others

GLOBAL REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Real World Evidence Solutions Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Real World Evidence Solutions Market Snippet by Therapeutic Area
    • 2.1.2. Real World Evidence Solutions Market Snippet by Component
    • 2.1.3. Real World Evidence Solutions Market Snippet by Application
    • 2.1.4. Real World Evidence Solutions Market Snippet by End Use
    • 2.1.5. Real World Evidence Solutions Market Snippet by Country
    • 2.1.6. Real World Evidence Solutions Market Snippet by Region
  • 2.2. Competitive Insights

3. Real World Evidence Solutions Key Market Trends

  • 3.1. Real World Evidence Solutions Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Real World Evidence Solutions Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Real World Evidence Solutions Market Opportunities
  • 3.4. Real World Evidence Solutions Market Future Trends

4. Real World Evidence Solutions Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Real World Evidence Solutions Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Real World Evidence Solutions Market Landscape

  • 6.1. Real World Evidence Solutions Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Real World Evidence Solutions Market - By Therapeutic Area

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapeutic Area, 2024&2032 (%)
    • 7.1.2. Respiratory
    • 7.1.3. Neurology
    • 7.1.4. Psychiatry
    • 7.1.5. Oncology
    • 7.1.6. Cardiology
    • 7.1.7. Diabetes
    • 7.1.8. Others

8. Real World Evidence Solutions Market - By Component

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Component, 2024&2032 (%)
    • 8.1.2. Data sets
    • 8.1.3. Services

9. Real World Evidence Solutions Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2024&2032 (%)
    • 9.1.2. Post Market Safety & Adverse Events Monitoring
    • 9.1.3. Reimbursement/Coverage and Regulatory Decision Making
    • 9.1.4. Drug Development & Approvals
    • 9.1.5. Medical Device Development & Approvals
    • 9.1.6. Clinical and regulatory decision-making

10. Real World Evidence Solutions Market - By End Use

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Component, 2024&2032 (%)
    • 10.1.2. Healthcare Payers
    • 10.1.3. Healthcare Providers
    • 10.1.4. Healthcare Companies (Pharmaceutical, Biopharmaceutical, Medical Device)
    • 10.1.5. Others

11. Real World Evidence Solutions Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024&2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Real World Evidence Solutions Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Real World Evidence Solutions Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Real World Evidence Solutions Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. PhilippinesMarket Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Real World Evidence Solutions Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Real World Evidence Solutions Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Real World Evidence Solutions Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Optum Inc.
    • 12.2.2. SAS Institute Inc.
    • 12.2.3. Parexel International Corporation
    • 12.2.4. Aetion, Inc.
    • 12.2.5. Oracle
    • 12.2.6. Trinity
    • 12.2.7. Icon Plc
    • 12.2.8. Merative
    • 12.2.9. IQVIA
    • 12.2.10. Cegedim Health Data
    • 12.2.11. Syneos Health
    • 12.2.12. Flatiron Health
    • 12.2.13. Cytel Inc.
    • 12.2.14. NTT DATA, Inc.
    • 12.2.15. Cognizant
    • 12.2.16. Medpace
    • 12.2.17. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제